// App-Quantinova.ai

984 : Ponatinib and Chemotherapy in Young Adults with De Novo Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. Results of Ponalfil Clinical Trial after Completion of Recruitment

Researchers

Presenter

  • Josep-Maria Ribera

Principal Investigators

  • Olga Garca

  • Pau Montesinos

  • Pilar Martinez

  • Jordi Esteve

  • Daniel Esteban

  • Mara Jos Moreno

  • Natalia Alonso

  • Jos Gonzlez-Campos

  • Arancha Bermdez

  • Anna Torrent

  • Joaquin Martinez-Lopez

  • Santiago Mercadal

  • Ramon Garcia-Sanz

Medical Centers

  • Hematology Department, Hospital Universitario La Fe de Valencia,, Valencia, Spain, Spain

  • Haematology department, 12 Octubre Hospital, Madrid, Spain

  • Dermatology Department, Hospital Clinic of Barcelona, Barcelona, Spain

  • Hospital Clinic i Provincial de Barcelona, Barcelona, Spain

  • Gastroenterology Department, Virgen de la Victoria Hospital, Málaga, Spain

  • Complexo Hospitalario Universitario de Santiago de Compostela, Santiago de Compostela, Spain

  • UGC Hematologia y Hemoterapia. Hospital Universitario Virgen del Rocio. Instituto de Biomedicina de Sevilla (IBIS)/CSIC/Universidad de Sevilla, Seville, Spain

  • Hematology Department, Universitary Hospital Marques de Valdecilla, Santander, Spain

  • Hematology and hemotherapy department, Hospital Universitario HLA Moncloa, Madrid, Spain

  • ICO-Hospital Duran i Reynals, LHospitalet de Llobregat, Spain

  • hematology Division, Hospital Universitaro de Salamanca, Salamanca, Spain

Locations

  • Spain

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

Biomarkers

  • Cluster of Differentiation 206

Drug/Treatment

  • Allmercap

  • Daunorubicin

  • Methotrexate

  • Vincristine

  • Prednisone

  • Etoposide

  • Etoposide phosphate

  • Ponatinib

  • ara-c

Outcome

  • N/A

Study Design

  • N/A

Phase

  • II

Study Id's

  • NCT02776605

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved